Malaga Cove Capital LLC Has $3.38 Million Stake in Hologic, Inc. (HOLX)
Malaga Cove Capital LLC raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 0.7% during the second quarter, according to its most recent filing with the SEC. The fund owned 74,427 shares of the medical equipment provider’s stock after buying an additional 496 shares during the period. Hologic comprises approximately 2.0% of Malaga Cove Capital LLC’s investment portfolio, making the stock its 9th largest position. Malaga Cove Capital LLC’s holdings in Hologic were worth $3,377,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Swiss National Bank boosted its position in Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock worth $43,747,000 after buying an additional 195,100 shares during the period. Earnest Partners LLC boosted its position in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock worth $8,734,000 after buying an additional 205,138 shares during the period. Lincoln Capital Corp purchased a new position in Hologic during the fourth quarter worth $377,000. KAMES CAPITAL plc purchased a new position in Hologic during the first quarter worth $718,000. Finally, LS Investment Advisors LLC boosted its position in Hologic by 10.9% in the first quarter. LS Investment Advisors LLC now owns 12,890 shares of the medical equipment provider’s stock worth $548,000 after buying an additional 1,268 shares during the period. Institutional investors and hedge funds own 94.04% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ HOLX) traded down 0.57% during trading on Friday, hitting $45.15. 338,449 shares of the company traded hands. The company has a 50-day moving average of $45.08 and a 200-day moving average of $42.70. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market capitalization of $12.64 billion, a PE ratio of 16.19 and a beta of 0.91.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The firm had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same quarter in the previous year, the business earned $0.47 earnings per share. The firm’s revenue was up 3.2% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post $2.01 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Malaga Cove Capital LLC Has $3.38 Million Stake in Hologic, Inc. (HOLX)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/07/21/malaga-cove-capital-llc-has-3-38-million-stake-in-hologic-inc-holx.html.
A number of research analysts have weighed in on HOLX shares. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, March 29th. Leerink Swann reiterated an “outperform” rating and set a $52.00 price objective on shares of Hologic in a research report on Thursday, March 30th. Needham & Company LLC boosted their price objective on shares of Hologic from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, April 4th. Barclays PLC set a $50.00 price objective on shares of Hologic and gave the company a “buy” rating in a research report on Wednesday, April 5th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $53.00 price objective on shares of Hologic in a research report on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. Hologic has a consensus rating of “Buy” and an average price target of $47.79.
In other Hologic news, Director Lawrence M. Levy sold 2,960 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $44.54, for a total value of $131,838.40. Following the completion of the sale, the director now owns 45,634 shares in the company, valued at $2,032,538.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,108 shares of company stock valued at $4,469,012. 0.79% of the stock is owned by company insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.